Patent · US Active

Substituted pyrimidines as IRE1 kinase inhibitors

US12391669B2 · kind B2 · utility

0Cited by

1References

18Claims

0Family size

Assignee

The Regents of the University of California et al. · US

Inventors

Bradley Backes · San Francisco, US
Feroz R. Papa · Oakland, US
Scott A. Oakes · San Francisco, US
Dustin J. Maly · Seattle, US

Key dates

Filing date	Aug 30, 2019
Grant date	Aug 19, 2025
Priority date	—
Expiry date	Aug 22, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are, inter alia, compounds modulating Inositol-Requiring Enzyme 1α (IRE1α) and IRE1β activity and methods of use thereof for treating IRE1α-mediated and IRE1β-mediated disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.